Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

On What Basis Did MRNA Stock Rise 8% Premarket?

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Shares of biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines Moderna Inc. (MRNA) were trading up 8.08% in the premarket session at $280.65 as of the last check. During the last trading session, Moderna stock closed at $ 259.67, up 5.28% or $ 13.01. In the course of the session, MRNA shares fluctuated between $245.505 and $261.22.

During the day, 14.19 million shares of MRNA stock were traded, which is higher than the company’s 50-day daily volume of 8.75 million and higher than its year-to-date volume of 10.63 million. MRNA stock has retreated 223.70% over the past 12 months, and it has gained 11.55% over the last week. A total of 109.31% has been gained by MRNA stock during the last six months, while a total of 62.43% has been gained during the last three months.

Currently, MRNA has returned 148.56 percent so far this year. The price to earnings ratio for the MRNA stock is 207.1 8. MRNA stock continued to rise as news had emerged that it has been added to S&P 500 and that quarterly earnings will be released soon.

When will MRNA be added to the S&P 500?

From a science research-stage company developing messenger RNA (mRNA) in the field of science over the past decade, Moderna has grown into an organization with a diverse clinical portfolio of vaccines and therapeutics in six different therapeutic areas. In addition to increasing the mRNA patent portfolio and launching a fully integrated manufacturing facility that would enable the Company to produce products both at scale and at unprecedented speed, MRNA has also expanded its intellectual property portfolio in the fields of lipid nanoparticle formulation and mRNA formulation.

In addition to its alliances with domestic and overseas partners, MRNA maintains partnerships with many Canadian and international organizations. This has allowed MRNA to pursue revolutionary science as well as rapid scale-up. Recent developments at MRNA have enabled their capabilities to result in an authorized use of a vaccine that was among the earliest and most effective against the COVID-19 pandemic.

Moderna will replace Alexion Pharmaceuticals Inc. on S&P 500 index, announced the company yesterday. MRNA will be included in the index prior to the opening of trading on Wednesday, July 21. Due to the acquisition of Alexion Pharmaceuticals by AstraZeneca Plc, MRNA has replaced Alexion on the charts pending final closing conditions.

MRNA to release quarterly results:

A live conference call and webcast will be held by Moderna on Thursday, August 5, 2021, at 8:00 am ET. MRNA will provide its corporate update and financial results ahead of the conference call.

In addition to the live conference call, a webcast of the call will also be available in the Investors section of the Moderna (MRNA) website under “Events and Presentations.” MRNA will make the archived webcast available on its website shortly after the conference call ends, and will remain accessible for one year following the call.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts



Download Free eBook For


100% free. stop anytime no spam